A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer

British Journal of Cancer

Volumn 63, Issue 5, 1991, Pages 794-798

  Smith, I E ^a   Jodrell, D I ^a   Mansi, J L ^a   Pearson, M C ^b   Walsh, G ^a   Ashley, S ^a   Sinnett, H D ^a   McKinna, J A ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN C; MITOXANTRONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMAN; MENOPAUSE; METHOTREXATE; MIDDLE AGE; MITOMYCINS; MITOXANTRONE; NEOPLASM STAGING;

EID: 0025729477     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1991.176     Document Type: Article

References (22)

1. AISNER, J., WEINBERG, M., PERLOFF, M. & 5 others (1987). Chemo therapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: a CALBG study. J. Clin. Oncol., 5, 1523
2. BENJAMIN, R. S., CHAWLA, S. P., EWER, M S., CARRASCO, C. H., MACKAY, B. & HOLMES, F. (1985). Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest. New Drugs, 3, 117
3. BONADONNA, G. & VALAGUSSA, P. (1981). Dose response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med., 384, 10
4. BRAMBILLA, C., DE LENA, M. ROSSI, A. & 4 others (1976). Response and survival in advanced breast cancer after two non-cross resistant combinations. Br. Med. J., 1, 801
5. COATES, A., GEBSKI, V., BISHOP, J. & 12 others (1987). Improving the quality of life during chemotherapy for advanced breast cancer. N. Engl. J. Med., 317, 1490
6. CUMMINGS, F. J., GELMAN, R. & HORTON, J. (1985). Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prog nostic factors. J. Clin. Oncol., 3, 932
7. HAYES, D. F. & HENDERSON, I. C. (1987). CAF in metastatic breast cancer: standard therapy or another effective regimen. Editorial. J. Clin. Oncol., 5, 1497
8. HAYWARD, J. L., CARBONE, P. P., HEUSON, J. -C., KUMAOKA, S., SEGALOFF, A. & RUBENS, R. D. (1977). Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer, 13, 89
9. HENDERSON, C. I., ALLEGRA, J. C., WOODCOCK, T. & 5 Others (1989). Randomised clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7, 560
10. JUDSON, I. R., POWLES, T. J., ASHLEY, S. E., GALLAGHER, C. & O’KEEFE, A. (1988). Mitomycin C, mitozantrone and methotrex ate (3M) for advanced breast cancer. A randomised crossover trial versus vincristine, adriamycin and cyclophosphamide (VAC). 3M is equally effective with reduced toxicity. Proc. Am. Soc. Clin. Oncol., 7, 10
11. KENNEDY, J. W., SORENSEN, S. G., RITCHIE, J. L., FOLLAND, E D. & HAMILTON, G. W. (1978). Radionuclide angiography for the eval uation of anthracycline therapy. Cancer Treat. Rep., 62, 941
12. MACAULAY, V. & SMITH, I. E. (1986). Advanced breast cancer. In: Randomised Trials in Cancer: a Critical Review by Sites. Slevin, M. L. & Staquet, M. J. (eds) pp. 273-357. Raven Press: New York
13. MUSS, H. B., WHITE, D. R., RICHARDS, F. & 5 others (1978). Adria mycin versus methotrexate in five-drug combination chemo therapy for advanced breast cancer. A randomised trial. Cancer, 42, 2141
14. PETO, R., PIKE, M. C., ARMITAGE, P. & 7 others (1977). Design and analysis of randomised clinical trials requiring prolonged obser vation of each patient. Part 2. Analysis and examples. Br. J. Cancer, 35, 1
15. POSNER, L. E., DUKART, G., GOLDBERG, J., BERNSTEIN, T. & CART WRIGHT, K. (1985). Mitoxantrone: an overview of safety and toxicity. Invest. New Drugs, 3, 123
16. SMALLEY, R. V., LEFANTE, J., BARTOLUCCI, A., CARPENTER, J., VOGEL, C. & KRAUSS, S. (1983). A comparison of cyclophos phamide, adriamycin and 5-FU (CAF) and cyclophosphamide, methotrexate, 5-FU, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res. Treat., 3, 209
17. STUART-HARRIS, R. C., BOZEK, T., PAVLIDIS, N. A. & SMITH, I. E. (1984a). Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Cancer Chemother. Pharmacol., 12, 1
18. STUART-HARRIS, R. C., PEARSON, M., SMITH, I. E. & OLSON, E. G. J. (1984b). Cardiotoxicity associated with mitoxantrone. Lancet, 2, 219
19. TANNOCK, I. F., BOYD, N. F., DEBOER, G. & 6 others (1988). A randomised trial of two dose levels of cyclophosphamide, metho trexate and fluorouracil chemotherapy for patients with meta static breast cancer. J. Clin. Oncol., 6, 1377
20. TORMEY, D. C., GELMAN, R., BAND, P. R. & 5 others (1982). Com parison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer, 50, 1235
21. VAN OOSTEROM, A T., POWLES, T. J., HAMERSMA, E., SMITH, I. E. & ENGELSMAN, E. (1979). A phase II study of mitomycin C in refractory advanced breast cancer. A multi-centre pilot study. In Breast Cancer - Experimental and Clinical Aspects. Mouridsen, H. T. & Palsof, T. (eds) pp. 275-276. Proceedings 2nd EORCT Breast Cancer Conference, Copenhagen, 1979. Pergamon Press, Copenhagen
22. WHO HANDBOOK ON REPORTING RESULTS OF CANCER TREATMENT (1979). WHO Offset Publication, No. 48, WHO: Geneva